Chronic itch has often been dismissed as a minor skin complaint; however, experts view it as a warning sign of deeper disease ...

Please provide your email address to receive an email when new articles are posted on . These studies are the first published using Dupixent in this indication. The primary endpoint was met by up to ...

Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the ...

The Food and Drug Administration has approved dupilumab for treating adults with prurigo nodularis, the first treatment approved for this indication, according to a press release from the ...

DelveInsight's Prurigo Nodularis Market Insights report includes a comprehensive understanding of current treatment practices, prurigo nodularis emerging drugs, market share of individual therapies, ...

Nemolizumab (Mitchga) is gearing up to be a potential new treatment for prurigo nodularis, with further phase 3 data supporting its efficacy and safety reported this month at the annual meeting of the ...

Dupixent, an interleukin-4 receptor alpha antagonist, is the first treatment indicated for prurigo nodularis. Credit: Getty Images. The Food and Drug Administration (FDA) has approved Dupixent ® ...

Please provide your email address to receive an email when new articles are posted on . Dupixent improved itch and skin lesions in patients with uncontrolled prurigo nodularis in a phase 3 clinical ...

The FDA approved the interleukin (IL)-31 monoclonal antibody nemolizumab (Nemluvio) for treating prurigo nodularis, drugmaker Galderma announced on Tuesday. The approval stipulates use in adults with ...

Sanofi and Regeneron’s Dupixent is on fire. A week after scoring the first FDA approval for eosinophilic esophagitis, the drug scored priority review for prurigo nodularis. If it wins the agency's ...

Newark, New Castle, USA, April 19, 2023 (GLOBE NEWSWIRE) -- According to a recent Growth Plus Reports assessment, the Prurigo Nodularis Treatment Market is estimated to reach US$ 3.40 billion by 2031, ...

This page lists all known medications that could potentially lead to 'Prurigo' as a side effect. It's important to note that mild side effects are quite common with medications. The medication(s) ...